Short answer
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal 2026 results cover the period ended September 30, 2026.
ARROWHEAD PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal 2026 results cover the period ended September 30, 2026
- Press release announces and discusses Arrowhead’s full-year financial results
- Investors should review Exhibit 99.1 for revenue, earnings, cash position and outlook details
Item EX-99.1 · Exhibit EX-99.1
- FY2026 revenue $450.8M, down from $829.4M, while net loss widened to $724.2M from $1.6M
- REDEMPLO adoption accelerating: prescriptions up 63% quarter over quarter, 950 cumulative U.S. prescriptions, 160M covered lives
- sHTG expansion advancing: FDA STAR acceptance enables six-month Priority Review, with potential U.S. launch targeted for Q2 2027
- New $400M term loan at SOFR plus 5.50%, replacing 15% debt and extending maturity to November 2031
- Cash resources $1.19B, but liabilities rose to $1.69B and stockholders’ equity declined to $50.3M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ARROWHEAD PHARMACEUTICALS, INC. 8-K filings
Get the next ARWR 8-K as it lands
Follow ARWR for push alerts, or ask the research agent what this filing means.